105 related articles for article (PubMed ID: 32915889)
21. Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures.
Bodle CR; Schamp JH; O'Brien JB; Hayes MP; Wu M; Doorn JA; Roman DL
SLAS Discov; 2018 Apr; 23(4):363-374. PubMed ID: 29351497
[TBL] [Abstract][Full Text] [Related]
22. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
23. High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer.
Itsumi M; Shiota M; Sekino Y; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Kajioka S; Uchiumi T; Eto M
Prostate; 2020 Aug; 80(11):885-894. PubMed ID: 32483877
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic serine-threonine kinase receptor-associated protein modulates the function of Ewing sarcoma protein through a novel mechanism.
Anumanthan G; Halder SK; Friedman DB; Datta PK
Cancer Res; 2006 Nov; 66(22):10824-32. PubMed ID: 17108118
[TBL] [Abstract][Full Text] [Related]
26. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.
Mitra P; Eckenrode JM; Mandal A; Jha AK; Salem SM; Leggas M; Rohr J
J Med Chem; 2018 Sep; 61(17):8001-8016. PubMed ID: 30114371
[TBL] [Abstract][Full Text] [Related]
27. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1.
Meisel Sharon S; Pozniak Y; Geiger T; Werner H
Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981
[TBL] [Abstract][Full Text] [Related]
28. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
Udager AM; DeMarzo AM; Shi Y; Hicks JL; Cao X; Siddiqui J; Jiang H; Chinnaiyan AM; Mehra R
Prostate; 2016 Jun; 76(9):845-53. PubMed ID: 27159573
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract][Full Text] [Related]
30. Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.
Booij TH; Klop MJ; Yan K; Szántai-Kis C; Szokol B; Orfi L; van de Water B; Keri G; Price LS
J Biomol Screen; 2016 Oct; 21(9):912-22. PubMed ID: 27412535
[TBL] [Abstract][Full Text] [Related]
31. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
[TBL] [Abstract][Full Text] [Related]
32. A fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53.
Tsuganezawa K; Nakagawa Y; Kato M; Taruya S; Takahashi F; Endoh M; Utata R; Mori M; Ogawa N; Honma T; Yokoyama S; Hashizume Y; Aoki M; Kasai T; Kigawa T; Kojima H; Okabe T; Nagano T; Tanaka A
J Biomol Screen; 2013 Feb; 18(2):191-8. PubMed ID: 22989451
[TBL] [Abstract][Full Text] [Related]
33. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
34. Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.
Xiao Q; Sun Y; Dobi A; Srivastava S; Wang W; Srivastava S; Ji Y; Hou J; Zhao GP; Li Y; Li H
Sci Rep; 2018 Aug; 8(1):12868. PubMed ID: 30150711
[TBL] [Abstract][Full Text] [Related]
35. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
[TBL] [Abstract][Full Text] [Related]
36. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
37. Aberrant laminin beta3 isoforms downstream of EWS-ETS fusion genes in Ewing family tumors.
Irifune H; Nishimori H; Watanabe G; Yoshida K; Ikeda T; Matsui C; Morohashi M; Kawaguchi S; Nagoya S; Wada T; Yamashita T; Nakamura Y; Tokino T
Cancer Biol Ther; 2005 Apr; 4(4):449-55. PubMed ID: 15846078
[TBL] [Abstract][Full Text] [Related]
38. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
39. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
40. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.
Gan W; Dai X; Lunardi A; Li Z; Inuzuka H; Liu P; Varmeh S; Zhang J; Cheng L; Sun Y; Asara JM; Beck AH; Huang J; Pandolfi PP; Wei W
Mol Cell; 2015 Sep; 59(6):917-30. PubMed ID: 26344095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
